["{\n\"step_by_step_thinking\": \"The question is about the pneumococcal vaccine PCV 23 polysaccharide showing best results in a specific group of people. From the provided documents, we can see that there are no direct mentions of Pneumococcal vaccine PCV 23 polysaccharide and its performance in people with Cystic fibrosis, Child less than 2 year age or Recurrent otitis media and sinusitis. However, we do know from [Pneumococcal serotyping] that the tetradecavalent vaccine gives a coverage superior to 80 percent in pneumonia, bacteremia, meningitis, and acute otitis media among other pathologies. Moreover, [Polyvalent pneumococcal polysaccharide vaccines] mentions that children over 2 years of age respond well to the vaccine. Therefore, it is likely that Pneumococcal vaccine PCV 23 polysaccharide shows its best results in people with high-risk populations such as sickle cell disease.\",\n\"answer_choice\": \"A\""]